Pancreatic Cancer Research

ResearcherKobe UniversityActive in the last 2 years

Takuya Mizumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8665-2776; OpenAlex author ID A5052839126. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 6 papers

Papers 12

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. Co-author DOI 10.1002/ags3.70100↗
  2. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  3. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… Co-author DOI 10.1016/j.gassur.2026.102410↗
  4. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18491-3↗
  5. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18718-3↗
  6. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18004↗
  7. Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery. Co-author DOI 10.1002/ags3.70059↗
  8. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2024.07.012↗
  9. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07471-z↗
  10. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Ad… Co-author DOI 10.1245/s10434-017-6274-8↗
  11. Pancreatic ductal adenocarcinoma with inferior vena cava invasion: a report of three resected cases. Co-author DOI 10.1186/s40792-017-0348-5↗
  12. [A Case of Pancreatic Cancer with Multiple Lymph Node Swelling Caused by Sarcoidosis]. Co-author PMID 29394809↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihide Nanno · 10 shared papers, 2017–2026 · strength 2.16
  2. Jun Ishida · 8 shared papers, 2024–2026 · strength 2.03
  3. Takumi Fukumoto · 11 shared papers, 2017–2026 · strength 2.03
  4. Hirochika Toyama · 9 shared papers, 2018–2026 · strength 1.95
  5. Hiroaki Yanagimoto · 7 shared papers, 2024–2026 · strength 1.75
  6. Sadaki Asari · 9 shared papers, 2017–2026 · strength 1.65
  7. Dongha Lee · 5 shared papers, 2025–2026 · strength 1.27
  8. Akira Fukutomi · 1 shared paper, 2026 · strength 0.29
  9. Dongha Lee · 1 shared paper, 2026 · strength 0.29
  10. Narikazu Boku · 1 shared paper, 2026 · strength 0.29
  11. Naoto Gotohda · 1 shared paper, 2026 · strength 0.29
  12. Takayuki Kodama · 1 shared paper, 2026 · strength 0.29
  13. Katsuhiko Uesaka · 1 shared paper, 2026 · strength 0.29
  14. Motofumi Tanaka · 3 shared papers, 2017–2018 · strength 0.19
  15. Keitaro Sofue · 2 shared papers, 2017–2018 · strength 0.13
  16. Sachiyo Shirakawa · 2 shared papers, 2017–2018 · strength 0.13
  17. Tadahiro Goto · 2 shared papers, 2017 · strength 0.12
  18. Yonson Ku · 2 shared papers, 2017 · strength 0.12
  19. Tomoaki Okimoto · 1 shared paper, 2019 · strength 0.09
  20. Kazuki Terashima · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.